Visual pathway in HD: Observational neuroimaging and neurophysiological study investigating the visual pathway in Huntington*s disease.
Recruiting
-To improve the understanding of alterations in the visual pathway in patients with HD in different disease stages.
-To investigate possible changes in brain function and structure in rest and in response to visual stimulation in patients with HD and healthy controls.
-To explore if visual cognitive impairments are related to changes in brain structure and brain function in premanifest and manifest HD.
Participants will undergo different clinical and neuropsychological(the study of how the brain affects how we think, feel, and behave)assessments during a single visits of approximately 3 hours. These assessments will examine the general physical and cognitive functioning. Furthermore, each participant will undergo a MRI-scan of the brain and a neurophysiological test (VEP)
Subtype: Observational Biomarker
Primary Purpose: Basic Science
Ages Eligible
for Study:
Sexes Eligible
for Study:
All
Accepts Healthy Volunteers:
yes
Between 18 and 65 years of age at time of visit
* Ability to undergo MRI scanning
* Written informed consent must be obtained from the participant;If the participant is a manifest HD gene carrier:
* Gene positive tested with CAG repeat length of * 36 in the HTT gene
* UHDRS-TMS > 5;If the participant is a premanifest HD gene carrier:
* Gene positive tested with CAG repeat length of * 36 in the HTT gene
* UHDRS-TMS * 5;If the participant is a control subject:
* Gene negative tested for HD or without family history of HD
* No other known cognitive, neurological or psychiatric disorders
Impaired primary visual ability (<0.5) or ophthalmic disorders
(including amblyopia or color vision deficiency)
* Additional major co-morbidities not related to HD
(e.g. cardiovascular diseases, hypertension, diabetes mellitus, and/or other neurological disorders)
* History of severe head injury
* Contra-indication for MRI (metallic implants/devices, claustrophobia)
* Participation in intervention trials
* Pregnancy
* Inability to understand the information about the protocol
LOCATION
NETHERLANDS
TRIAL SITE: Leids Universitair Medisch Centrum
Albinusdreef 2, Leiden 2333ZA, NL
